- Home
- RXST
RXST
RxSight Inc.
as 04-18-2025 1:42pm EST
RxSight Inc is a commercial-stage medical technology company dedicated towards improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture and sale of light adjustable lenses and related capital equipment.
| Founded: | 1997 | Country: | United States |
| Employees: | N/A | City: | ALISO VIEJO |
| Market Cap: | 1.0B | IPO Year: | 2021 |
| Target Price: | $38.50 | AVG Volume (30 days): | 1.2M |
| Analyst Decision: | Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.71 | EPS Growth: | N/A |
| 52 Week Low/High: | $13.50 - $66.54 | Next Earning Date: | 05-07-2025 |
| Revenue: | $139,927,000 | Revenue Growth: | 57.09% |
| Revenue Growth (this year): | 24.34% | Revenue Growth (next year): | 21.83% |
Stock Insider Trading Activity of RxSight Inc. (RXST)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Fountain Tamara | RXST | Director | Mar 12 '25 | Sell | $25.71 | 7,000 | $180,001.50 | 24,793 | |
| Maniar Shweta | RXST | Director | Jan 22 '25 | Sell | $30.87 | 3,519 | $108,618.16 | 7,383 |
Latest RxSight Inc. News
RXST Breaking Stock News: Dive into RXST Ticker-Specific Updates for Smart Investing
MT Newswires
4 days ago
Piper Sandler Initiates RxSight at Neutral With $18 Price Target
MT Newswires
10 days ago
Needham Cuts Price Target on RxSight to $22 From $43, Keeps Buy Rating
MT Newswires
10 days ago
UBS Downgrades RxSight to Neutral From Buy, Cuts Price Target to $16 From $45
Investing.com
15 days ago
JP Morgan downgrades RxSight on market, competitive pressures
TipRanks
15 days ago
Block upgraded, Nvidia downgraded: Wall Street’s top analyst calls
Simply Wall St.
15 days ago
Is RxSight, Inc. (NASDAQ:RXST) Trading At A 39% Discount?
MT Newswires
15 days ago
JPMorgan Downgrades RxSight to Underweight From Overweight, Adjusts Price Target to $17 From $40
GuruFocus.com
15 days ago
RxSight Inc (RXST) Q1 2025 Earnings Call Highlights: Strong Year-Over-Year Growth Amid Revised ...
Compare RXST vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RXST RxSight Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.